New drug may improve HSA survival rates

“A breakthrough trial at the University of Minnesota testing a new UMN-developed drug resulted in improved survival rates for dogs diagnosed with a cancer called hemangiosarcoma (HSA)…This is likely the most significant advance in the treatment of canine HSA in the last three decades,” said study co-author Jaime Modiano, V.M.D., Ph.D. professor in the University of Minnesota College of Veterinary Medicine and member of the Masonic Cancer Center, University of Minnesota.”

Drug developed at University of Minnesota increases survival in dogs with cancer